Preemie Hypothermia for Neonatal Encephalopathy

Status Completed

Clinical Trial Summary

This study is a randomized, controlled trial to assess safety and effectiveness of whole body hypothermia for 72 hours in preterm infants 33-35 weeks gestational age (GA) who present at <6 hours postnatal age with moderate to severe neonatal encephalopathy (NE). The study will enroll infants with signs of NE at 18 NICHD Neonatal Research Network sites, and randomly assign them to either receive hypothermia or participate in a non-cooled control group.

Clinical Trial Description

Most clinical studies of neonatal encephalopathy (NE) and potential interventions have focused on infants ≥36 weeks GA. Although many interventions have been suggested and assessed for prevention or palliation of NE, the only one currently supported by rigorous clinical evidence to improve outcome in human newborns has been hypothermia implemented at <6 hours of postnatal age and maintained for 72 hrs. Data about diagnosis, frequency, severity, and outcome of NE in infants 33-35 weeks GA are sparse. This trial will assess safety and effectiveness of whole body hypothermia for 72 hours in preterm infants 33-35 weeks gestational age (GA) who present at <6 hrs postnatal age with moderate to severe neonatal encephalopathy. Infants 33 0/7 to 35 6/7 weeks GA (best obstetrical estimate) and greater than or equal to 1500 grams birth weight (selected to minimize potential difficulties placing esophageal probe) who meet clinical, biochemical and neurologic criteria for moderate to severe NE will be randomized to either whole body hypothermia or participate in a non-cooled control group. The primary outcome will be death or moderate to severe disability at 18-22 months corrected age. The presence or absence of disability will be determined by the standard NRN interdisciplinary follow-up exam. Secondary Study includes determining an association between MRI detectable injury and neurodevelopment at 18-22 months. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01793129
Study type	Interventional
Source	NICHD Neonatal Research Network
Contact
Status	Completed
Phase	N/A
Start date	May 2015
Completion date	December 9, 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04994652` - Video- Or Direct Laryngoscopy for Endotracheal Intubation in Newborns	N/A
Completed	`NCT02064712` - Determining an Optimal Weaning Method of Nasal Continuous Positive Airway Pressure in Preterm Neonates	N/A
Withdrawn	`NCT01335919` - Neonatal Non-Invasive Hemoglobin Determination	N/A
Terminated	`NCT01192776` - Optimizing (Longer, Deeper) Cooling for Neonatal Hypoxic-Ischemic Encephalopathy(HIE)	N/A
Completed	`NCT00114543` - Trial of Aggressive Versus Conservative Phototherapy in Infants <1,000 Grams Birth Weight	Phase 3
Completed	`NCT00011362` - Dexamethasone Therapy in VLBW Infants at Risk of CLD	Phase 3
Recruiting	`NCT05001334` - Effect of Kangaroo Care on Phyiological Weight Loss in Term Newborns	N/A
Completed	`NCT01193270` - Vitamin E for Extremely Preterm Infants	Phase 1
Completed	`NCT00005772` - Whole-Body Cooling for Birth Asphyxia in Term Infants	Phase 3
Terminated	`NCT00005776` - Inhaled Nitric Oxide Study for Respiratory Failure in Newborns	Phase 3
Completed	`NCT01203423` - Persistent Pulmonary Hypertension of the Newborn (PPHN) Observational Study
Completed	`NCT06120062` - Effect of Swaddling and Inhaling Breast Milk Odour on the Pain and Comfort
Completed	`NCT00820677` - Newborn Health Information Study	N/A
Active, not recruiting	`NCT00189384` - Efficacy Study of Community-Based Treatment of Serious Bacterial Infections in Young Infants	Phase 3
Completed	`NCT01203410` - Prediction of Jaundice in Term Infants
Recruiting	`NCT03745963` - The Influence of Skin-to-skin Contact on Cortical Activity During Painful Procedures on Preterm Infants in the NICU	Phase 3
Completed	`NCT04050384` - Effect of a Vibratory Stimulus on Mitigating Nociception-specific Responses to Skin Puncture in Neonates	N/A
Withdrawn	`NCT00598429` - Inhaled PGE1 in Neonatal Hypoxemic Respiratory Failure	Phase 2
Completed	`NCT01223287` - Physiologic Definition of Bronchopulmonary Dysplasia	N/A
Terminated	`NCT00005774` - Early Surfactant to Reduce Use of Mechanical Breathing in Low Birth Weight Infants	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.